Skip to main content

Advertisement

Log in

Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis

  • Original Article - Guidelines
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objective of the study was to develop evidence-based and practical recommendations for the detection and management of comorbidity in patients with rheumatoid arthritis (RA) in daily practice. We used a modified RAND/UCLA methodology and systematic review (SR). The process map and specific recommendations, based on the SR, were established in discussion groups. A two round Delphi survey permitted (1) to prioritize the recommendations, (2) to refine them, and (3) to evaluate their agreement by a large group of users. The recommendations cover: (1) which comorbidities should be investigated in clinical practice at the first and following visits (including treatments, risk factors and patient’s features that might interfere with RA management); (2) how and when should comorbidities and risk factors be investigated; (3) how to manage specific comorbidities, related or non-related to RA, including major adverse events of RA treatment, and to promote health (general and musculoskeletal health); and (4) specific recommendations to assure an integral care approach for RA patients with any comorbidity, such as health care models for chronic inflammatory patients, early arthritis units, relationships with primary care, specialized nursing care, and self-management. These recommendations are intended to guide rheumatologists, patients, and other stakeholders, on the early diagnosis and management of comorbidity in RA, in order to improve disease outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. van den Akker M, Buntinx F, Roos S, Knottnerus JA (2001) Problems in determining occurrence rates of multimorbidity. J Clin Epidemiol 54(7):675–679

    Article  PubMed  Google Scholar 

  2. Michaud K, Wolfe F (2007) Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21(5):885–906

    Article  PubMed  Google Scholar 

  3. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11(3):229

    Article  PubMed Central  PubMed  Google Scholar 

  4. Perez Edo L, Alonso Ruiz A, Roig Vilaseca D, Garcia Vadillo A, Guanabens Gay N, Peris P et al (2011) Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 7(6):357–379

    Article  PubMed  Google Scholar 

  5. Gomez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Canete JD et al (2011) Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin 7(5):284–298

    Article  PubMed  Google Scholar 

  6. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331

    Article  CAS  PubMed  Google Scholar 

  7. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Spanish Society of Rheumatology. Clinical practice guideline for the management of rheumatoid arthritis in Spain. Spain 2011. Dec 12, 2013. http://www.ser.es/ArchivosDESCARGABLES/Proyectos/GUIPCAR_2007/GUIPCAR2007-ENG.pdf

  9. Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R (2003) Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 62(9):897–900

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Mikuls TR, Saag KG (2001) Comorbidity in rheumatoid arthritis. Rheum Dis Clin N Am 27(2):283–303

    Article  CAS  Google Scholar 

  11. Centre for Evidence-based Medicine. Oxford Centre for Evidence-based Medicine—Levels of Evidence (2009). [Cited 2013]. http://www.cebm.net/index.aspx?o=1025

  12. Descalzo MA, Carbonell J, Gonzalez-Alvaro I, Sanmarti R, Balsa A, Hernandez-Barrera V et al (2012) Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(3):321–330

    Article  Google Scholar 

  13. Baron M, Schieir O, Hudson M, Steele R, Janelle-Montcalm A, Bernstein J et al (2009) Evaluation of the clinimetric properties of the early inflammatory arthritis—self-administered comorbidity questionnaire. Rheumatology (Oxf) 48(4):390–394

    Article  Google Scholar 

  14. Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 65(9):924–933

    Article  PubMed  Google Scholar 

  15. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163

    Article  PubMed  Google Scholar 

  16. Turesson C (2013) Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 25(3):360–366

    Article  CAS  PubMed  Google Scholar 

  17. Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology (Oxf) 52(1):99–110

    Article  Google Scholar 

  18. Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21(5):907–927

    Article  PubMed  Google Scholar 

  19. Nakamura Y, Suda T, Kaida Y, Kono M, Hozumi H, Hashimoto D et al (2012) Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med 106(8):1164–1169

    Article  PubMed  Google Scholar 

  20. EULAR Textbook on Rheumatic Diseases. European League Against Rheumatism, editor: BMJ Group; 2012

  21. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43(12):2776–2784

    Article  CAS  PubMed  Google Scholar 

  22. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 15(4):155–160

    Article  PubMed  Google Scholar 

  23. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54(10):3104–3112

    Article  PubMed  Google Scholar 

  24. Mazzantini M, Talarico R, Doveri M, Consensi A, Cazzato M, Bazzichi L et al (2010) Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol 37(11):2232–2236

    Article  PubMed  Google Scholar 

  25. McKeown E, Bykerk VP, De Leon F, Bonner A, Thorne C, Hitchon CA et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxf) 51(9):1662–1669

    Article  CAS  Google Scholar 

  26. Wolfe F, Hauser W, Hassett AL, Katz RS, Walitt BT (2011) The development of fibromyalgia—I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 152(2):291–299

    Article  PubMed  Google Scholar 

  27. Wolfe F, Michaud K (2004) Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol 31(4):695–700

    PubMed  Google Scholar 

  28. Dhir V, Lawrence A, Aggarwal A, Misra R (2009) Fibromyalgia is common and adversely affects pain and fatigue perception in North Indian patients with rheumatoid arthritis. J Rheumatol 36(11):2443–2448

    Article  PubMed  Google Scholar 

  29. Coury F, Rossat A, Tebib A, Letroublon MC, Gagnard A, Fantino B et al (2009) Rheumatoid arthritis and fibromyalgia: a frequent unrelated association complicating disease management. J Rheumatol 36(1):58–62

    PubMed  Google Scholar 

  30. Roig Vilaseca D, Hoces Otero C (2008) Effect of the coexistence of fibromyalgia in the DAS28 Index in women with rheumatoid arthritis. Reumatol Clin 4(3):96–99

    Article  PubMed  Google Scholar 

  31. Bori Segura G, Hernandez Cruz B, Gobbo M, Lanas Arbeloa A, Salazar Paramo M, Teran Estrada L et al (2009) Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology. Reumatol Clin 5(1):3–12

    Article  PubMed  Google Scholar 

  32. Ranzolin A, Brenol JC, Bredemeier M, Guarienti J, Rizzatti M, Feldman D et al (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 61(6):794–800

    Article  PubMed  Google Scholar 

  33. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D et al (2008) EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67(4):536–541

    Article  CAS  PubMed  Google Scholar 

  34. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW et al (2007) EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(3):377–388

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64(5):669–681

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62(12):1145–1155

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Del Olmo L, Hernandez B, Galindo-Izquierdo M, Tebar D, Balsa A, Carmona L (2012) Peri-operative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis. Rev Esp Cir Ortop Traumatol 56(5):393–412

    PubMed  Google Scholar 

  38. Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: a systematic review. Musculoskelet Care 11(4):238–247

  39. Cramp F, Hewlett S, Almeida C, Kirwan JR, Choy EH, Chalder T et al (2013) Non-pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev 8:CD008322

    PubMed  Google Scholar 

  40. Gordon MM, Thomson EA, Madhok R, Capell HA (2002) Can intervention modify adverse lifestyle variables in a rheumatoid population? Results of a pilot study. Ann Rheum Dis 61(1):66–69

    Article  PubMed Central  PubMed  Google Scholar 

  41. Mody GM, Brooks PM (2012) Improving musculoskeletal health: global issues. Best Pract Res Clin Rheumatol 26(2):237–249

    Article  PubMed  Google Scholar 

  42. Desai SS, Myles JD, Kaplan MJ (2012) Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 14(6):R270

    Article  PubMed Central  PubMed  Google Scholar 

  43. Kaur S, White S, Bartold PM (2013) Periodontal disease and rheumatoid arthritis: a systematic review. J Dent Res 92(5):399–408

    Article  CAS  PubMed  Google Scholar 

  44. Mangani I, Cesari M, Kritchevsky SB, Maraldi C, Carter CS, Atkinson HH et al (2006) Physical exercise and comorbidity. Results from the fitness and arthritis in seniors trial (FAST). Aging Clin Exp Res 18(5):374–380

    Article  PubMed  Google Scholar 

  45. Reckner Olsson A, Skogh T, Wingren G (2001) Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis 60(10):934–939

    Article  CAS  PubMed  Google Scholar 

  46. Ribeiro J, Leao A, Novaes AB (2005) Periodontal infection as a possible severity factor for rheumatoid arthritis. J Clin Periodontol 32(4):412–416

    Article  PubMed  Google Scholar 

  47. Pasma A, Van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: A systematic review. Semin Arthritis Rheum 43(1):18–28

    Article  PubMed  Google Scholar 

  48. Knittle K, De Gucht V, Maes S (2012) Lifestyle- and behaviour-change interventions in musculoskeletal conditions. Best Pract Res Clin Rheumatol 26(3):293–304

    Article  PubMed  Google Scholar 

  49. Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA et al (2012) Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol 18(4):180–184

    PubMed  Google Scholar 

  50. Carmona Ortells L, Laffon Roca A (1994) Local therapy in Sjögren’s syndrome. A practical review. Rev Esp Reumatol 21:259–262

    Google Scholar 

  51. Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R et al (2013) Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal 18(4):e680–e685

    Article  PubMed Central  PubMed  Google Scholar 

  52. Blake DJ, Maisiak R, Koplan A, Alarcon GS, Brown S (1988) Sexual dysfunction among patients with arthritis. Clin Rheumatol 7(1):50–60

    Article  CAS  PubMed  Google Scholar 

  53. Aguirre MA, Velez A, Romero M, Collantes E (2002) Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol 29(8):1793–1794

    PubMed  Google Scholar 

  54. Yilmaz H, Polat HA, Yilmaz SD, Erkin G, Kucuksen S, Salli A et al (2012) Evaluation of sexual dysfunction in women with rheumatoid arthritis: a controlled study. J Sex Med 9(10):2664–2670

    Article  PubMed  Google Scholar 

  55. Hill J, Bird H, Thorpe R (2003) Effects of rheumatoid arthritis on sexual activity and relationships. Rheumatology (Oxf) 42(2):280–286

    Article  CAS  Google Scholar 

  56. Gossec L, Solano C, Paternotte S, Beauvais C, Gaudin P, von Krause G et al (2012) Elaboration and validation of a questionnaire (Qualisex) to assess the impact of rheumatoid arthritis on sexuality with patient involvement. Clin Exp Rheumatol 30(4):505–513

    PubMed  Google Scholar 

  57. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 4(4):CD007848

    PubMed  Google Scholar 

  58. Marks JL, van der Heijde DM, Colebatch AN, Buchbinder R, Edwards CJ (2012) Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. J Rheumatol Suppl 90:81–84

    Article  CAS  PubMed  Google Scholar 

  59. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T et al (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 5:CD000951

    PubMed  Google Scholar 

  60. Gotzsche PC, Johansen HK (2004) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 3:CD000189

    PubMed  Google Scholar 

  61. Adams K, Bombardier C, van der Heijde DM (2012) Safety of pain therapy during pregnancy and lactation in patients with inflammatory arthritis: a systematic literature review. J Rheumatol Suppl 90:59–61

    Article  PubMed  Google Scholar 

  62. Loza E, Jover JA, Rodriguez L, Carmona L (2009) Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. Semin Arthritis Rheum 38(4):312–319

    Article  PubMed  Google Scholar 

  63. Wijlhuizen GJ, Perenboom RJ, Garre FG, Heerkens YF, van Meeteren N (2012) Impact of multimorbidity on functioning: evaluating the ICF core set approach in an empirical study of people with rheumatic diseases. J Rehabil Med 44(8):664–668

    Article  PubMed  Google Scholar 

  64. McDaid O, Hanly MJ, Richardson K, Kee F, Kenny RA, Savva GM (2013) The effect of multiple chronic conditions on self-rated health, disability and quality of life among the older populations of Northern Ireland and the Republic of Ireland: a comparison of two nationally representative cross-sectional surveys. BMJ Open 3(6). doi:10.1136/bmjopen-2013-002571

  65. Burt J, Rick J, Blakeman T, Protheroe J, Roland M, Bower P (2014) Care plans and care planning in long-term conditions: a conceptual model. Prim Health Care Res Dev 5(4):342–354

  66. Newbould J, Burt J, Bower P, Blakeman T, Kennedy A, Rogers A et al (2012) Experiences of care planning in England: interviews with patients with long term conditions. BMC Fam Pract 13:71

    Article  PubMed Central  PubMed  Google Scholar 

  67. Villaverde V, Descalzo MA, Carmona L, Bascones M, Carbonell J (2011) Characteristics of early arthritis units that may be associated with better referral efficiency: survey of SERAP units. Reumatol Clin 7(4):236–240

    Article  PubMed  Google Scholar 

  68. Villaverde V, Carmona L, Lopez Robledillo JC, Serrano S, Gobbo M (2013) Motivations and objections to implement a spondyloarthritis integrated care pathway. A qualitative study with primary care physicians. Rheumatol Clin 9(2):85–89

    Google Scholar 

  69. van Eijk-Hustings Y, van Tubergen A, Bostrom C, Braychenko E, Buss B, Felix J et al (2012) EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis 71(1):13–19

    Article  PubMed  Google Scholar 

  70. Bonavita V, De Simone R (2008) Towards a definition of comorbidity in the light of clinical complexity. Neurol Sci 29(Suppl 1):S99–S102

    Article  PubMed  Google Scholar 

  71. Gullick NJ, Scott DL (2011) Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25(4):469–483

    Article  PubMed  Google Scholar 

  72. Hyrich K, Symmons D, Watson K, Silman A (2006) Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65(7):895–898

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Radner H, Smolen JS, Aletaha D (2011) Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxf) 50(2):381–388

    Article  Google Scholar 

  74. Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G (2006) Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity. J Rheumatol 33(8):1488–1495

    PubMed  Google Scholar 

  75. Pereira IA, Mota LM, Cruz BA, Brenol CV, Fronza LS, Bertolo MB et al (2012) 2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol 52(4):474–495

    PubMed  Google Scholar 

  76. Esselens G, Westhovens R, Verschueren P (2009) Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskelet Care 7(1):1–16

    Article  Google Scholar 

  77. Development group of the stroke prevention Guideline (2008) Iberoamerican Cochrane Centre—coordinator. Clinical practice guideline for primary and secondary prevention of stroke. Quality Plan for the National Health System of the Ministry of Health and Consumer Affairs; Catalan Agency for Health Technology Assessment and Research, Madrid (2008)

  78. Martín-Martínez MA, González-Juanatey C, Castañeda S, Llorca J, Ferraz-Amaro I, Fernández-Gutiérrez B et al (2014) Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis. Scientific evidence and expert opinion. Semin Arthritis Rheum 44(1):1–8

  79. Singapore Ministry of Health (2010) Cancer screening. Singapore: Singapore Ministry of Health (Nov 12, 2013). http://www.guideline.gov/content.aspx?id=39346&search=cancer+screening

  80. Spanish Society of Rheumatology (2011) Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain. National Guidelines Clearinghouse—Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Aug 10, 2013). http://www.guideline.gov/content.aspx?id=36829&search=rheumatoid

  81. Working group of the Clinical Practice Guideline for type 2 Diabetes (2008) Clinical Practice Guideline on type 2 Diabetes. Madrid: Health Technologies Assessment Agency of the Basque Country

  82. National Collaborating Centre for Mental Health (2009) Depression in adults with a chronic physical health problem. Treatment and management. National Institute for Health and Clinical Excellence (NICE), London, UK; (Nov 12, 2013); Clinical guideline; no. 91. http://www.guideline.gov/content.aspx?id=15522&search=depression

  83. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1905–1913

    Article  CAS  PubMed  Google Scholar 

  84. Joint Task Force on Practice Parameters, American Academy of Allergy Asthma and Immunology, American College of Allergy Asthma and Immunology, Joint Council of Allergy Asthma and Immunology. Drug allergy: an updated practice parameter. National Guideline Clearinghouse—Agency for Healthcare Research and Quality (AHRQ), Rockville, MD; (Nov 12, 2013). http://www.guideline.gov/content.aspx?id=38446&search=allergies+and+drug+allergies

  85. National Institute for Health and Care Excellence (NICE) (2008) Early identification and management of chronic kidney disease in adults in primary and secondary care. National Institute for Health and Care Excellence, UK (Jan 22, 14); NICE clinical guideline 73. http://guidance.nice.org.uk/cg73

  86. Medical Services Commission (2011) Abnormal liver chemistry—evaluation and interpretation. Victoria, BC (Jan 22, 14). http://www.guideline.gov/content.aspx?id=38889&search=liver

  87. HealthPartners Dental Group (2011) HealthPartners Dental Group and Clinics periodontal risk assessment guideline. Minneapolis, MN (Jan 22, 14). http://www.guideline.gov/content.aspx?id=35131&search=periodontal+disease

  88. Commission MS (2010) Thyroid function tests: diagnoses and monitoring of thyroid function disorders in adults. Victoria, BC (Jan 22, 2014). http://www.guideline.gov/content.aspx?id=38907&search=thyroid

  89. U.S. Preventive Services Task Force recommendation statement (2009) Screening for impaired visual acuity in older adults. Ann Intern Med 151(1):37–43

    Article  Google Scholar 

  90. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM (2014) A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 43(6):701–712

  91. Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquivias G, Perez-Aísa A et al (2014) Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG). Gastroenterol Hepatol 37(3):107–127

  92. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69(11):1913–1919

    Article  PubMed  Google Scholar 

  93. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62(11):1515–1526

    Article  Google Scholar 

  94. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The consensus statement was promoted and funded by the Madrilenian Society of Rheumatology (SORCOM). ROCHE supported the logistics of the meetings and did not intervene in the design, analysis, or editing of the manuscript.

Conflict of interest

Dr. Carmona reports Grants from ROCHE, during the conduct of the study; Grants from MSD, Grants from ABBVIE, Grants from PFIZER, outside the submitted work. Dr. Lajas reports Grants from ROCHE, during the conduct of the study; Grants from MSD, outside the submitted work. Dr. Andreu reports personal fees from ROCHE, during the conduct of the study; personal fees from Abbvie, personal fees from Roche, personal fees from MSD, personal fees from UCB, outside the submitted work. Dr. Balsa reports Grants and personal fees from Roche, during the conduct of the study; Grants and personal fees from Pfizer, Grants and personal fees from Abbvie, personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Novartis, outside the submitted work. Dr. Gonzalez-Alvaro reports Grants and personal fees from Bristol-Myers Squibb, Grants and personal fees from Roche, Grants and personal fees from UCB Pharma, personal fees and other from Abbvie, personal fees and other from Pfizer, other from MSD, outside the submitted work. Dr. Jover reports Grants and personal fees from Roche, during the conduct of the study; Grants and personal fees from Abbvie, Grants from MSD, Grants from Roche, outside the submitted work. Dr. Martinez-Lopez reports Grants from Roche, during the conduct of the study. Dr. Ortiz reports Grants from ROCHE, during the conduct of the study. Dr. Toledano reports Grants from ROCHE, during the conduct of the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Santos Castañeda.

Additional information

Estíbaliz Loza and Cristina Lajas have contributed equally to this work.

On behalf of the GECOAR Study Group.

Electronic supplementary material

Appendix: GECOAR Study Group (in alphabetical order)

Appendix: GECOAR Study Group (in alphabetical order)

Aguado Acín, Pilar; Ahijado Guzmán, Mª del Pilar; Almodóvar González, Raquel; Andreu, José Luis; Aragón Diez, Angel; Bachiller Corral, Javier; Balsa, Alejandro; Barbadillo Mateos, Carmen; Brito Brito, M. Elia; Calvo Aranda, Enrique; Carmona, Loreto; Castañeda, Santos; Crespo Echevarría, Manuel; De Miguel Mendieta, Eugenio; Díaz Oca, Alberto; Garcia de Vicuña, Rosario; García González, Javier; Garcia Vadillo, Alberto; Gonzalez Crespo, Maria Rosa; González Fernández, Carlos; González-Álvaro, Isidoro; Illera, Oscar; Jover, Juan Ángel; Lajas, Cristina; Loza, Estíbaliz; Martínez López, Juan Antonio; Mata Llord, Jose De La; Mateo, Isabel; Morado Quiñoa, Inmaculada C.; Morillas López, Luis; Movasat Hajkhan, Atusa; Mulero Mendoza, Juan; Navío Marco, Maria Teresa; Orte, Javier; Ortiz, Ana María; Revenga Martinez, Marcelino; Rey Rey, José; Richi, Patricia; Rivera, Javier; Rodriguez Heredia, José Manuel; Romero, Fredeswinda; Rosales Rosado, Zulema; Sánchez Sánchez, Marina; Toledano, Esther; Usón, Jacqueline; Valenciano, Ana Cruz; Valero, Marta; Vicente Rabaneda, Esther F.; Villaverde, Virginia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Loza, E., Lajas, C., Andreu, J.L. et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int 35, 445–458 (2015). https://doi.org/10.1007/s00296-014-3196-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3196-7

Keywords

Navigation